Pfizer Acquires Lucira Health for $36.4 Million in Bankruptcy Auction
Summary
Laboratory industry report that Pfizer acquired Lucira Health for $36.4 million in a bankruptcy auction on April 20. It says Lucira secured the first Emergency Use Authorization (EUA) for an at-home COVID-19 test product in November 2020, and that in February its COVID-19 & Flu Home Test became the first at-home assay to detect and differentiate influenza A, influenza B, and SARS-CoV-2 to receive EUA clearance for over-the-counter (OTC) use. It says the California-based diagnostics developer had to file for Chapter 11 bankruptcy protection just two days before the announcement of the combo test approval. The article points readers to the Laboratory Industry Report for more on the Lucira Health story.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Pfizer Acquires Lucira Health for $36.4 Million in Bankruptcy Auction.”
Original at www.g2intelligence.com. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/g2-lucira-pfizer-bankruptcy-sale-2023-f93b899177/
, SHA-256 3e3502ad9b1683a0db1111df6ce65addbc964f08d0142257e348eba22de72c9c.Full text
Pfizer Acquires Lucira Health for $36.4 Million in Bankruptcy Auction It has been an eventful year for Lucira Health, the company that secured the very first Emergency Use Authorization (EUA) for an at-home COVID-19 test product back in November 2020. In February, the Lucira COVID-19 & Flu Home Test became the first at-home assay for detecting and differentiating between influenza A, influenza B, and SARS-CoV-2 to receive EUA clearance for over-the-counter (OTC) use. The positive news was tempered by its occurrence just as flu season was ending . Having banked on an August approval date, the California-based diagnostics developer had to file for Chapter 11 bankruptcy protection just two days before announcement of the combo test approval. On April 20, Lucira Health’s story took another major turn when Pfizer acquired it for $36.4 million in a bankruptcy auction. For more laboratory business news, including more on the Lucira Health story, see our Laboratory Industry Report . Subscribe or sign up for a free trial for access.
File and source
- File
- g2-lucira-pfizer-bankruptcy-sale-2023.html
- Size
- 104,077 bytes
- SHA-256
- 3e3502ad9b1683a0db1111df6ce65addbc964f08d0142257e348eba22de72c9c
- Original
- www.g2intelligence.com